24/7 Patient Assistance: 760-405-8205
24/7 Patient Assistance: 760-405-8205
Hospitals & Clinics
specialties & services
Dr. Syma Iqbal did her medical schooling at the Keck School of Medicine of USC and completed her residency program at the Cedar-Sinai Medical Center. Then, he did a fellowship at the University of Southern California. She is specialized in Medical Oncology and board certified in Oncology. Dr. Iqbal has been in practice for more than 20 years and is affiliated with the USC Norris Comprehensive Cancer Center and Keck Hospital of USC. During her career, she has also contributed to 6 research publications.
Keck of USC
Medical School
Cedars-Sinai Medical Center
Residency
University of Southern California - LAC+USC Medical Center
Fellowship
American Board of Internal Medicine - Oncology
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II...
Philip, P. A.,Goldman, B.,Ramanathan, R. K.,Lenz, H. J.,Lowy, A. M.,Whitehead, R. P.,Wakatsuki, T.,Iqbal, S.,Gaur, R.,Benedetti, J. K.,Blanke, C. D.; Cancer. 2014 Jul 22.
See more >>
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
Sunakawa, Y.,Wakatsuki, T.,Yang, D.,Zhang, W.,Ning, Y.,Stintzing, S.,Stremitzer, S.,Yamauchi, S.,Sebio, A.,El-Khoueiry, R.,Iqbal, S.,Barzi, A.,Gerger, A.,Stotz, M.,Azu...; Pharmacogenet. Genomics. 2014 Sep 10.
See more >>
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
Iqbal, S.,Lenz, H. J.,Gandara, D. R.,Shibata, S. I.,Groshen, S.,Synold, T. W.,Newman, E. M.; Cancer Chemother. Pharmacol.. 2013 Jul.
See more >>Memberships
American College of Physicians
American Society of Clinical Oncology
